TY - JOUR
T1 - Een vergelijking van wereldwijd toegepaste prognostische risicoclassificatiesystemen en de prevalentie van metastasen op PSMA PET/CT bij patiënten met nieuw gediagnosticeerde prostaatkanker
AU - Luining, Wietske I.
AU - de Weijer, Tessa R.
AU - Boevé, Liselotte M. S.
AU - Hagens, Marinus J.
AU - Meijer, Dennie
AU - Ettema, Rosemarijn H.
AU - Knol, Remco J. J.
AU - Roeleveld, Ton A.
AU - Srbljin, Sandra
AU - Weltings, Saskia
AU - Koppes, José C. C.
AU - van Moorselaar, Reindert J. A.
AU - van Leeuwen, Pim J.
AU - Cysouw, Matthijs C. F.
AU - Oprea-Lager, Daniela E.
AU - Vis, André N.
N1 - Publisher Copyright:
© The Author(s) 2025.
PY - 2025/10
Y1 - 2025/10
N2 - Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. This study evaluated the predictive value of risk groups (low-, intermediate-, and high-risk) within four RCSs (EAU, NCCN, CPG, and CAPRA) for detecting metastases on primary PSMA-PET/CT. Metastases were observed in 35% (931/2.630) of patients. Prevalence among intermediate- and high-risk groups ranged from 12 to 46%. Two RCSs subdivided these groups: metastatic disease was found in 5.8%, 13%, 22%, and 62% for favorable intermediate-, unfavorable intermediate-, high-, and very-high-risk PCa (NCCN); and 6.9%, 13%, 21%, and 60% for the corresponding CPG groups. This study highlights the importance of detailed risk stratification, and PSMA-PET/CT for primary staging should be reserved for patients with unfavorable intermediate-risk prostate cancer or higher.
AB - Various risk classification systems (RCSs) are used globally to stratify newly diagnosed patients with prostate cancer (PCa) into prognostic groups. This study evaluated the predictive value of risk groups (low-, intermediate-, and high-risk) within four RCSs (EAU, NCCN, CPG, and CAPRA) for detecting metastases on primary PSMA-PET/CT. Metastases were observed in 35% (931/2.630) of patients. Prevalence among intermediate- and high-risk groups ranged from 12 to 46%. Two RCSs subdivided these groups: metastatic disease was found in 5.8%, 13%, 22%, and 62% for favorable intermediate-, unfavorable intermediate-, high-, and very-high-risk PCa (NCCN); and 6.9%, 13%, 21%, and 60% for the corresponding CPG groups. This study highlights the importance of detailed risk stratification, and PSMA-PET/CT for primary staging should be reserved for patients with unfavorable intermediate-risk prostate cancer or higher.
KW - Metastatic disease
KW - PSMA PET/CT
KW - Prostate cancer
KW - Risk classification systems
UR - https://www.scopus.com/pages/publications/105001983532
U2 - 10.1007/s13629-025-00469-1
DO - 10.1007/s13629-025-00469-1
M3 - Article
SN - 2211-3037
VL - 15
SP - 120
EP - 128
JO - Tijdschrift voor urologie
JF - Tijdschrift voor urologie
IS - 6-7
ER -
